Literature DB >> 34185285

Meningioma Tumor Microenvironment.

Sajad Sahab-Negah1,2, Ali Gorji3,4,5,6.   

Abstract

The tumor microenvironment consists of noncancerous cells, such as immune cells and fibroblasts, and the proteins produced by these cells as well as the extracellular matrix components in the environment around a tumor. Tumor influences the behavior of the cells present in the surrounding environment, while the cells in the tumor microenvironment modulate the evolution of the tumor. Little is known about the microenvironment of meningioma, the most common benign intracranial tumor. Here, we review the current knowledge of the tumor microenvironment of meningioma and discusses its importance in meningioma tumorigenesis as well as in the designation of novel therapeutic approaches.

Entities:  

Keywords:  Cancer; Extracellular matrix; Growth factors; Immune cells; Immune response; Inflammation; Macrophages; Nitric oxide synthase; Peripheral immune tolerance; Stroma; T cells; Tumor angiogenesis apoptosis; Tumor infiltration; Vascular endothelial growth factor

Mesh:

Year:  2020        PMID: 34185285     DOI: 10.1007/978-3-030-59038-3_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  98 in total

Review 1.  The Ki-67 protein: from the known and the unknown.

Authors:  T Scholzen; J Gerdes
Journal:  J Cell Physiol       Date:  2000-03       Impact factor: 6.384

Review 2.  Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression.

Authors:  Etsu Tashiro; Ayako Tsuchiya; Masaya Imoto
Journal:  Cancer Sci       Date:  2007-03-14       Impact factor: 6.716

3.  Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression.

Authors:  Gang Cheng; Leiming Zhang; Wenying Lv; Chao Dong; Yaming Wang; Jianning Zhang
Journal:  Med Oncol       Date:  2014-12-13       Impact factor: 3.064

4.  Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67.

Authors:  W Roggendorf; T Schuster; J Peiffer
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

5.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

6.  Cyclin D1 immunoreactivity in meningiomas.

Authors:  Sanja Milenković; Tatjana Marinkovic; Milan B Jovanovic; Slavisa Djuricic; Ivana I Berisavac; Iva Berisavac
Journal:  Cell Mol Neurobiol       Date:  2008-04-01       Impact factor: 5.046

7.  History of head trauma and risk of intracranial meningioma: population-based case-control study.

Authors:  L E Phillips; T D Koepsell; G van Belle; W A Kukull; J-A Gehrels; W T Longstreth
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

Review 8.  Epidemiology of meningiomas.

Authors:  I Baldi; J Engelhardt; C Bonnet; L Bauchet; E Berteaud; A Grüber; H Loiseau
Journal:  Neurochirurgie       Date:  2014-09-22       Impact factor: 1.553

9.  Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas.

Authors:  L A Langford; C S Cooksley; F DeMonte
Journal:  Hum Pathol       Date:  1996-04       Impact factor: 3.466

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  2 in total

1.  M2-Macrophage-Derived Exosomes Promote Meningioma Progression through TGF-β Signaling Pathway.

Authors:  Xiao-Hong Fu; Jian-Ping Li; Xue-Ying Li; Yan Tan; Min Zhao; Shao-Fu Zhang; Xue-Dong Wu; Jian-Guo Xu
Journal:  J Immunol Res       Date:  2022-05-20       Impact factor: 4.493

Review 2.  CDK 4/6 inhibitors for the treatment of meningioma.

Authors:  Jacob S Young; Reilly L Kidwell; Allison Zheng; Alex F Haddad; Manish K Aghi; David R Raleigh; Jessica D Schulte; Nicholas A Butowski
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.